Management of Erectile Dysfunction in Diabetes: An Update for 2008

被引:9
作者
Price, David [1 ]
Hackett, Geoffrey [1 ]
机构
[1] ABM Univ Trust, Morriston Hosp, Swansea SA6 6NL, W Glam, Wales
关键词
D O I
10.1007/s11892-008-0076-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumescence occurs as a result of nitric oxide (NO)mediated smooth muscle relaxation of the erectile tissue leading to engorgement of the corpus cavernosum. The process is initiated by neuronal NO release and maintained by NO released by the local vascular endothelium. Erectile dysfunction (ED) affects 30% to 40% of diabetic men and occurs as a result of endothelial dysfunction and autonomic neuropathy. The close association with endothelial dysfunction means ED is an early marker of cardiovascular risk. Managing ED is easy and must be part of a diabetes care service. Phosphodiesterase type 5 inhibitors are the treatment of choice, but are effective in only 50% to 60% of diabetic men. The reasons for non-responsiveness remain uncertain and research is needed in this area. There has been much recent interest in the potential relationship between late-onset hypogonadism and diabetes, but there is no,evidence of a causal relationship and the evidence in favor of treating borderline hypogonadism in diabetes is limited.
引用
收藏
页码:437 / 443
页数:7
相关论文
共 44 条
[1]   Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF [J].
Angulo, J ;
Cuevas, P ;
Fernández, A ;
Gabancho, S ;
Allona, A ;
Martín-Morales, A ;
Moncada, I ;
Videla, S ;
de Tejada, IS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 312 (04) :1202-1208
[2]   REASONS FOR PATIENT DROP-OUT FROM AN INTRACAVERNOUS AUTOINJECTION PROGRAM FOR ERECTILE DYSFUNCTION [J].
ARMSTRONG, DKB ;
CONVERY, AG ;
DINSMORE, WW .
BRITISH JOURNAL OF UROLOGY, 1994, 74 (01) :99-101
[3]   Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus [J].
Boulton, AJM ;
Selam, JL ;
Sweeney, M ;
Ziegler, D .
DIABETOLOGIA, 2001, 44 (10) :1296-1301
[4]   Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses [J].
Brock, GB ;
McMahon, CG ;
Chen, KK ;
Costigan, T ;
Shen, W ;
Watkins, V ;
Anglin, G ;
Whitaker, S .
JOURNAL OF UROLOGY, 2002, 168 (04) :1332-1336
[5]   The efficacy and safety of tadalafil: an update [J].
Carson, CC ;
Rajfer, J ;
Eardley, I ;
Carrier, S ;
Denne, JS ;
Walker, DJ ;
Shen, W ;
Cordell, WH .
BJU INTERNATIONAL, 2004, 93 (09) :1276-1281
[6]   Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes [J].
Cartledge, JJ ;
Eardley, I ;
Morrison, JFB .
BJU INTERNATIONAL, 2001, 87 (04) :402-407
[7]   Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study [J].
Dean, John ;
Hackett, Geoffrey I. ;
Gentile, Vincezo ;
Pirozzi-Farina, Furio ;
Rosen, Raymond C. ;
Zhao, Yanli ;
Warner, Margaret R. ;
Beardsworth, Anthony .
JOURNAL OF SEXUAL MEDICINE, 2006, 3 (04) :650-661
[8]   Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease [J].
DeBusk, RF ;
Pepine, CJ ;
Glasser, DB ;
Shpilsky, A ;
DeRiesthal, H ;
Sweeney, M .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (02) :147-153
[9]   IMPAIRED NEUROGENIC AND ENDOTHELIUM-MEDIATED RELAXATION OF PENILE SMOOTH-MUSCLE FROM DIABETIC MEN WITH IMPOTENCE [J].
DETEJADA, IS ;
GOLDSTEIN, I ;
AZADZOI, K ;
KRANE, RJ ;
COHEN, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (16) :1025-1030
[10]   An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy [J].
Eardley, I ;
Mirone, V ;
Montorsi, F ;
Ralph, D ;
Kell, P ;
Warner, MR ;
Zhao, YL ;
Beardsworth, A .
BJU INTERNATIONAL, 2005, 96 (09) :1323-1332